8-KLeadership ChangesExhibits & Filings

AFLAC INC 8-K Report, Executive Changes (Nov 14, 2017)

Filed November 14, 2017For Securities:AFL

Summary

Aflac Incorporated (AFL) announced key executive and board changes in an 8-K filing dated November 14, 2017. Kriss Cloninger III, currently President of Aflac Incorporated, will be resigning from his role as President and retiring from the Board of Directors, effective December 31, 2017. This marks the departure of a significant figure within the company's leadership. Concurrently, the Board appointed Katherine T. Rohrer to the Board of Directors, effective immediately. Dr. Rohrer's appointment brings new expertise to the board, with her term set to conclude at the 2018 Annual Meeting of Shareholders. Her compensation will align with the company's established non-employee director compensation plans. Investors should monitor how these leadership transitions may impact strategic direction and operational execution in the coming periods.

Key Highlights

  • 1Kriss Cloninger III to resign as President of Aflac Incorporated effective December 31, 2017.
  • 2Kriss Cloninger III to retire from the Board of Directors effective December 31, 2017.
  • 3Katherine T. Rohrer appointed to the Board of Directors, effective November 14, 2017.
  • 4Dr. Rohrer's board term will expire at the 2018 Annual Meeting of Shareholders.
  • 5Dr. Rohrer's compensation will be in accordance with the company's standard non-employee director compensation plans.
  • 6The specific board committee assignments for Dr. Rohrer are yet to be determined.
  • 7The filing includes a press release as Exhibit 99.1 detailing these announcements.

Frequently Asked Questions

Aflac announced the resignation of Kriss Cloninger III as President, effective December 31, 2017, and his retirement from the Board of Directors on the same date. Additionally, Katherine T. Rohrer has been appointed to the Board of Directors, effective November 14, 2017.

Katherine T. Rohrer has been appointed to the Board of Directors of Aflac Incorporated. Her term as a director will conclude at the Company's Annual Meeting of Shareholders in 2018. Her specific committee assignments are pending.

Dr. Rohrer will receive compensation and be eligible for applicable plans as a non-employee director, following the company's established non-employee director compensation plans and practices as outlined in the March 16, 2017, Proxy Statement.

Kriss Cloninger III held the position of President of Aflac Incorporated and was a member of the Board of Directors. His resignation as President and retirement from the Board represents a significant change in the company's senior leadership and governance structure.